Donohue J, Homge M, Kernan N A
Charles A. Dana Marrow Transplant Unit, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Blood. 1993 Aug 1;82(3):1023-9.
To help elucidate the mechanism responsible for graft failure (GF) following a T-cell depleted bone marrow transplant (BMT) from an unrelated donor, five patients (2 chronic myelogenous leukemia, 1 acute undifferentiated leukemia, 2 myelodysplastic syndrome) who experienced this complication were studied. All patients were HLA class I identical with their donors as determined by serology and one-dimensional isoelectric focusing (IEF); two were serologically matched with their donors for HLA class II antigens, whereas three donor-recipient pairs were serologically mismatched for one HLA-DR antigen. All patients received total body irradiation (fractionated, 1,500 rads), VP-16 (750 mg/m2), and cyclophosphamide (120 mg/kg) pre-BMT and antithymocyte globulin (15 mg/kg every other day) and methylprednisolone (2 mg/kg) post-BMT. Three patients experienced primary nonengraftment and two experienced secondary GF. Peripheral blood mononuclear cells obtained from the patients at the time of GF were studied to examine their functional and phenotypic characteristics. Emerging cells were of host origin and were found to be specifically cytotoxic to donor target cells and suppressive to the in vitro growth of donor BM, especially in the cases of primary nonengraftment. Peripheral blood mononuclear cells from these patients were expanded to form T-cell lines (TcLs). The cytotoxic activities of TcLs were tested in the presence of blocking MoAbs directed against various HLA determinants in an attempt to determine if HLA antigens expressed on donor cells were the target for cytotoxicity. The observed cytotoxic activity was blocked by antibodies to HLA-B, -C (1 patient), HLA-DR (1 patient), and HLA-DQ (1 patient). In two cases, antidonor cytotoxicity could not be blocked by MoAb directed against HLA-A, -B, -C, or -DR. Phenotypic characterization of four successfully maintained TcLs showed 100% CD3+ cells with 100% CD4+ (3 patients) or 50% CD4+/50% CD8+ (1 patient). In two of the three patients with 100% CD4+ cells, antidonor cytotoxicity was blocked by an anti-HLA class II MoAb. In contrast to our previous findings in cases of GF following T-cell-depleted HLA nonidentical family member BMT in which host T cells were CD8+ and cytotoxicity was directed against HLA class I antigens, our present study indicates host T cells emerging at the time of GF following BMT from an HLA class I IEF-identical unrelated donor can be of the CD4+ subset and seem to be capable of recognizing antigenic disparities in the HLA class II region.
为了帮助阐明无关供体的T细胞去除型骨髓移植(BMT)后移植物失败(GF)的机制,对5例发生该并发症的患者(2例慢性粒细胞白血病、1例急性未分化白血病、2例骨髓增生异常综合征)进行了研究。通过血清学和一维等电聚焦(IEF)确定,所有患者与供体的HLA I类抗原相同;2例患者与供体的HLA II类抗原血清学匹配,而3对供体-受体在一种HLA-DR抗原上血清学不匹配。所有患者在BMT前接受了全身照射(分次,1500拉德)、VP-16(750mg/m²)和环磷酰胺(120mg/kg),并在BMT后接受了抗胸腺细胞球蛋白(每隔一天15mg/kg)和甲泼尼龙(2mg/kg)。3例患者发生原发性植入失败,2例发生继发性GF。在GF发生时从患者获取外周血单个核细胞,研究其功能和表型特征。发现出现的细胞来源于宿主,对供体靶细胞具有特异性细胞毒性,并抑制供体骨髓的体外生长,尤其是在原发性植入失败的病例中。将这些患者的外周血单个核细胞进行扩增以形成T细胞系(TcL)。在针对各种HLA决定簇的封闭性单克隆抗体存在的情况下测试TcL的细胞毒性活性,以试图确定供体细胞上表达的HLA抗原是否是细胞毒性的靶标。观察到的细胞毒性活性被针对HLA-B、-C(1例患者)、HLA-DR(1例患者)和HLA-DQ(1例患者)的抗体阻断。在2例病例中,抗供体细胞毒性不能被针对HLA-A、-B、-C或-DR的单克隆抗体阻断。对4个成功维持的TcL的表型特征分析显示,细胞为100% CD3+,其中3例患者为100% CD4+,1例患者为50% CD4+/50% CD8+。在3例100% CD4+细胞的患者中的2例,抗供体细胞毒性被抗HLA II类单克隆抗体阻断。与我们之前在T细胞去除型HLA不匹配家庭成员BMT后GF病例中的发现相反,在那些病例中宿主T细胞为CD8+,细胞毒性针对HLA I类抗原,我们目前的研究表明,在来自HLA I类IEF相同的无关供体的BMT后GF发生时出现的宿主T细胞可以是CD4+亚群,并且似乎能够识别HLA II类区域中的抗原差异。